Active Ingredient(s): Insulin Degludec + Liraglutide
FDA Approved: * November 21, 2016
Pharm Company: * NOVO NORDISK INC
Category: Diabetes

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Xultophy Overview

Liraglutide/insulin degludek (trade name Xultophy) is a combination drug consisting of: Liraglutide, a long-acting glucagon-like peptide-1 receptor agonist Insulin degludec, an ultralong-acting basal insulin analogue This pharmacy-related article is a stub. You can help Wikipedia by expanding it. v t e

Read more Xultophy Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Liraglutide/insulin_degludec

Recent Xultophy Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Insulin Degludec + Liraglutide
  • Injection: 100units + 3.6mg
  • Solution: 300 Units/3ml + 10.8mg/3ml (100 Units/ml + 3.6mg/ml)
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Drugs with one or more similar ingredients: (8 results)

Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. Site content is Copyright © 2005-2017 MedsChat.com and is protected under U.S. and International Copyright laws. All Rights Reserved. This page was last updated on 20 October 2017.

We are committed to your privacy.

Copyright © 2005-2017 All Rights Reserved. MedsChat® and The People's Medicine Community® are registered trademarks of Limelight Innovations L.L.C.